SurModics Inc (SRDX)

[mcmike]

Notes from the Goldman Sachs 26th Annual Global Healthcare Conf.

Site-specific drug delivery focusing on the convergence of drugs and medical devices

74 companies have licensed the company's technology

8 different polymers to deliver drugs; bio-degradeable or non, hydrophilic or non-hydrophilic

82 products currently generating revenues

Cypher is sole drug eluting stent marketed in Japan, the second largest market in the world. Exclusivity for the next year and a half.

Acquisition of InnoRx & their ophthalmology product to combat macular degeneration and other retinal diseases like diabetic macular edema

64 products licensed but not yet released to the marketplace
52 projects not yet licensed but being supported by our partners

Islet cell encapsulation: Novocell. promising animal data has led to an IMD application and forthcoming human clinical trials.

Working with JNJ on next 2 generations of Cypher vascular stent product.